摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

长春罗定 | 15228-71-4

中文名称
长春罗定
中文别名
异长春碱
英文名称
leurosidine
英文别名
Vinrosidina;methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17R)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
长春罗定化学式
CAS
15228-71-4
化学式
C46H58N4O9
mdl
——
分子量
810.988
InChiKey
JXLYSJRDGCGARV-KSNABSRWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    208-211 °c (dec.).

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    59
  • 可旋转键数:
    10
  • 环数:
    9.0
  • sp3杂化的碳原子比例:
    0.59
  • 拓扑面积:
    154
  • 氢给体数:
    3
  • 氢受体数:
    12

SDS

SDS:b12c9ba948f87947b4b4493abc3d03ef
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    [EN] EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF
    [FR] CONJUGUÉ DE MÉDICAMENT À BASE D'EPSILON-POLY-L-LYSINE, INTERMÉDIAIRE DE CELUI-CI, ET SON APPLICATION
    [ZH] 一种基于ε-聚-L-赖氨酸的药物偶联物、其中间体及其应用
    摘要:
    本发明公开了一种基于ε-聚-L-赖氨酸的药物偶联物、其中间体及其应用。本发明提供了一种如式(I)所示的具有基团偶联数量可控和基团偶联位点可控的ε-聚-L-赖氨酸衍生物-药物偶联物。本发明的药物偶联物具有肾脏清除率低、肝脾清除率低、血浆半衰期长、快速在病灶蓄积有效药物浓度和治疗效果更好的效果优势中的一个或多个。
    公开号:
    WO2023078464A1
  • 作为产物:
    描述:
    Ervamycine; 11-甲氧基水甘草碱盐酸 、 iron(III) chloride hexahydrate 、 苯亚硒酸酐 作用下, 以 为溶剂, 反应 3.0h, 生成 长春罗定长春花碱
    参考文献:
    名称:
    (-)-Jerantinines A,C和E,(-)-16-甲氧基烟豆碱,(-)-文多林和(+)-长春碱的不对称总合成
    摘要:
    简明和含氧的合成立体控制策略白坚木属和长春花生物碱,通过立体选择性分子间逆电子需求[4 + 2]环加成,一个具有挑战性的α,β不饱和酮吲哚化重排具有优异的区域选择性和立体选择性,和一个高效的Pd / C催化一锅级联反应。该策略已通过抗肿瘤药物(+)-长春碱和其他五种含氧曲霉精生物碱的高效不对称合成得到证明。
    DOI:
    10.1021/acs.orglett.7b03694
点击查看最新优质反应信息

文献信息

  • Stereoselective Conversion of Anhydrovinblastine into Vinblastine Utilizing an Anti-vinblastine Monoclonal Antibody as a Chiral Mould
    作者:Tatsuya Shirahama、Takeyuki Kohno、Tomohiro Kaijima、Yasuo Nagaoka、Daisuke Morimoto、Kazumasa Hirata、Shinichi Uesato
    DOI:10.1248/cpb.54.665
    日期:——
    Dimeric indole alkaloid, anhydrovinblastine, which can be obtained from catharanthine and vindoline in a high yield, was converted stereoselectively into vinblastine through alternating oxidation-reduction with oxygen and NaBH(3)CN in the presence of anti-vinblastine monoclonal antibody.
    二聚吲哚生物碱,脱水长春碱,可以从catharanthine和长春花碱以高收率获得,通过在存在抗长春碱单克隆抗体的情况下,通过与氧气和NaBH(3)CN交替氧化还原,将立体选择性地转化为长春碱。
  • Vinblastine 20′ Amides: Synthetic Analogues That Maintain or Improve Potency and Simultaneously Overcome Pgp-Derived Efflux and Resistance
    作者:John C. Lukesh、Daniel W. Carney、Huijun Dong、R. Matthew Cross、Vyom Shukla、Katharine K. Duncan、Shouliang Yang、Daniel M. Brody、Manuela M. Brütsch、Aleksandar Radakovic、Dale L. Boger
    DOI:10.1021/acs.jmedchem.7b00958
    日期:2017.9.14
    A series of 180 vinblastine 20' amides were prepared in three steps from commercially available starting materials, systematically exploring a typically inaccessible site in the molecule enlisting a powerful functionalization strategy. Clear structure activity relationships and a structural model were developed in the studies which provided many such 20' amides that exhibit substantial and some even remarkable enhancements in potency, many that exhibit further improvements in activity against a Pgp overexpressing resistant cancer cell line, and an important subset of the vinblastine analogues that display little or no differential in activity against a matched pair of vinblastine sensitive and resistant (Pgp overexpressing) cell lines. The improvements in potency directly correlated with target tubulin binding affinity, and the reduction in differential functional activity against the sensitive and Pgp overexpressing resistant cell lines was found to correlate directly with an impact on Pgp-derived efflux.
  • Kutney, James Peter; Choi, Lewis Siu Leung; Nakano, Jun, Heterocycles, 1988, vol. 27, # 8, p. 1845 - 1854
    作者:Kutney, James Peter、Choi, Lewis Siu Leung、Nakano, Jun、Tsukamoto, Hiroki、McHugh, Michael、Boulet, Camille Andre
    DOI:——
    日期:——
  • Asymmetric Total Syntheses of (−)-Jerantinines A, C, and E, (−)-16-Methoxytabersonine, (−)-Vindoline, and (+)-Vinblastine
    作者:Nengzhong Wang、Jianrong Liu、Chen Wang、Leiyang Bai、Xuefeng Jiang
    DOI:10.1021/acs.orglett.7b03694
    日期:2018.1.5
    concise and stereocontrolled strategy for the syntheses of oxygenated Aspidosperma and Vinca alkaloids, via a stereoselective intermolecular inverse-electron-demand [4 + 2] cycloaddition, a challenging α,β-unsaturated ketone indolization rearrangement with excellent regio- and stereoselectivity, and an efficient Pd/C-catalyzed one-pot cascade reaction. The strategy has been demonstrated by the efficient
    简明和含氧的合成立体控制策略白坚木属和长春花生物碱,通过立体选择性分子间逆电子需求[4 + 2]环加成,一个具有挑战性的α,β不饱和酮吲哚化重排具有优异的区域选择性和立体选择性,和一个高效的Pd / C催化一锅级联反应。该策略已通过抗肿瘤药物(+)-长春碱和其他五种含氧曲霉精生物碱的高效不对称合成得到证明。
  • [EN] EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF<br/>[FR] CONJUGUÉ DE MÉDICAMENT À BASE D'EPSILON-POLY-L-LYSINE, INTERMÉDIAIRE DE CELUI-CI, ET SON APPLICATION<br/>[ZH] 一种基于ε-聚-L-赖氨酸的药物偶联物、其中间体及其应用
    申请人:[en]SHANGHAI BEST-LINK BIOSCIENCE, LLC;[zh]上海弼领生物技术有限公司
    公开号:WO2023078464A1
    公开(公告)日:2023-05-11
    本发明公开了一种基于ε-聚-L-赖氨酸的药物偶联物、其中间体及其应用。本发明提供了一种如式(I)所示的具有基团偶联数量可控和基团偶联位点可控的ε-聚-L-赖氨酸衍生物-药物偶联物。本发明的药物偶联物具有肾脏清除率低、肝脾清除率低、血浆半衰期长、快速在病灶蓄积有效药物浓度和治疗效果更好的效果优势中的一个或多个。
查看更多

同类化合物

长春西醇 长春西碱 长春花胺 长春花碱 长春罗定 长春素 长春磷汀 长春甘酯 长春瑞宾 长春氮芥 长春氟宁酒石酸盐 长春氟宁 长春曲醇酸 长春曲醇 长春新碱 长春匹定硫酸盐 脱水长春碱 脱乙酰基长春碱酰肼 硫酸长春碱 硫酸长春新碱 硫酸长春地辛 硫酸长春地辛 甲酰基-环氧长春碱 二(N-亚乙基长春地辛)二硫醚 O4-去乙酰基-3',4'-二去氢-4'-脱氧-C'-去甲长春花碱 N-去甲基长春碱 N-(O-4-去乙酰基-长春碱-23-酰基)-L-亮氨酸乙酯 N-(4-叠氮基-3-碘水杨酰)-N'-beta-氨基乙基长春地辛 4-去乙酰基长春花碱 3-(((2-((4-叠氮基-2-硝基苯基)氨基)乙基)氨基)羰基)-O4-去乙酰基-3-去(甲氧羰基)-长春花碱 3''-(beta-氯乙基)-2'',4''-二氧代-3,5''-螺恶唑烷-4-去乙酰氧基长春碱 2,5-哌嗪二酮,1,4-二甲基-3-亚甲基- (3'a,4'a)-4'-脱氧-3',4'-环氧-12'-羟基-长春花碱 12'-iodovinblastine 12'-thiomethylvinblastine 20',20'-difluoro-4'-deoxyvinblastine methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[(cyclobutanecarbonylamino)methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[[(4-chlorobenzoyl)amino]methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-10-[[(4-methoxybenzoyl)amino]methyl]-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[(3,3-dimethylbutanoylamino)methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-8-methyl-10-[[(4-nitrobenzoyl)amino]methyl]-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-8-methyl-10-[(3-methylbutanoylamino)methyl]-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-[[(4-fluorobenzoyl)amino]methyl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[(butanoylamino)methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[[(3-chlorobenzoyl)amino]methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[(cyclopropanecarbonylamino)methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[[(2-chlorobenzoyl)amino]methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[(2,2-dimethylpropanoylamino)methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-8-methyl-10-[(propanoylamino)methyl]-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-8-methyl-10-[(pyridine-4-carbonylamino)methyl]-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate